You would think that the annual report is proof read
Wouldn't you!
Although recruitment has finished in the three monotherapy trials (Dep Docetaxel Dep Cabazitaxel and Dep Irinotecan), only patients in Dep Docetaxel and Dep Cabazitaxel monotherapy trials have completed treatment. Patients are still being treated in the monotherapy trial for Dep Irinotecan
Our chairman Rob Thomas stated the following in the annual report
Unbelievable
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
13.0¢ |
Change
0.005(4.00%) |
Mkt cap ! $54.36M | |||
| Open | High | Low | Value | Volume |
| 13.0¢ | 13.0¢ | 12.0¢ | $53.97K | 420.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 70507 | 12.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 13.0¢ | 493895 | 3 |
View Market Depth
| Last trade - 15.14pm 19/09/2025 (20 minute delay) ? |
| SPL (ASX) Chart |